Deal Watch: Roche Partners With Rheos To Develop Novel Immunometabolism Therapeutics
Executive Summary
Roche will obtain options to license candidates discovered and optimized by Rheos under the collaboration. Jazz acquires US rights to PharmaMar SCLC candidate, while Biogen teams with both Ionis and Catalyst.
You may also be interested in...
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Deal Watch: AbbVie Partners With Gedeon Richter In Neuropsychiatry
Seeing strong sales with legacy Allergan’s Vraylar, AbbVie teams with Gedeon Richter on novel dopamine receptor modulators. AB Studio, CR Biopharma partner on COVID-19 neutralizing antibody.
Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug
Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.